Your browser is no longer supported. Please, upgrade your browser.
Mind Medicine (MindMed) Inc.
Index- P/E- EPS (ttm)- Insider Own6.56% Shs Outstand326.13M Perf Week-16.11%
Market Cap1.07B Forward P/E- EPS next Y- Insider Trans0.00% Shs Float286.31M Perf Month25.67%
Income- PEG- EPS next Q- Inst Own0.57% Short Float- Perf Quarter-4.65%
Sales- P/S- EPS this Y- Inst Trans- Short Ratio- Perf Half Y261.71%
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year684.13%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.29 - 5.77 Perf YTD7.54%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-43.15% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low1026.76% ATR0.52
Employees22 Current Ratio- Sales Q/Q- Oper. Margin- RSI (14)51.03 Volatility16.25% 15.77%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.93 Prev Close3.41
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume6.03M Price3.28
Recom- SMA205.16% SMA5011.48% SMA20066.96% Volume5,607,081 Change-3.81%
May-05-21 07:30AM  
May-04-21 10:07AM  
May-03-21 03:01PM  
Apr-28-21 06:43AM  
Mind Medicine (MindMed) Inc., a psychedelic medicine biotech company, discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of innovative treatments based on psychedelic substances, including Psilocybin, LSD, MDMA, DMT, and an Ibogaine derivative, 18-MC. The company is headquartered in New York, New York.